Dilemmas in the compassionate supply of investigational cancer drugs
- 8 September 2014
- journal article
- Published by Wiley in Internal Medicine Journal
- Vol. 44 (9) , 841-845
Abstract
In Australia, patients who want to access medicines that are not yet approved have only two options: to enrol in a clinical trial if they are eligible, or obtain their medicine through ‘compassionate supply’, which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, either prior to regulatory approval or government reimbursement.Keywords
This publication has 14 references indexed in Scilit:
- Co‐funded expanded access programmes for new oncology drugs: creating a two‐tier system for Australian cancer patients?Internal Medicine Journal, 2013
- Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast CancerJournal of Mammary Gland Biology and Neoplasia, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Cancer and the Constitution — Choice at Life's EndNew England Journal of Medicine, 2007
- Just Say No to Drugs: The Abigail Alliance and the Attempted Abolition of the Food and Drug AdministrationBiotechnology Law Report, 2007
- Access before Approval — A Right to Take Experimental Drugs?New England Journal of Medicine, 2006
- Failing the Public Health — Rofecoxib, Merck, and the FDANew England Journal of Medicine, 2004
- Treatment of Patients With Metastatic Renal Carcinoma With a Combination of Subcutaneous Interleukin-2 and Interferon Alfa With or Without FluorouracilJournal of Clinical Oncology, 2000
- The Saga of ThalidomideNew England Journal of Medicine, 1962